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ABSTRACT 
Background: Sentinel node (SLN) status is the most important prognostic factor for early-stage melanoma patients. It 
will influence follow-up and may change therapy. Positive SLNs present different degrees of involvement so that sub-
groups of patients may have minimal SLN invasion. The aim of this study was to evaluate survival in subgroups with 
minimally involved SLNs and to compare them to negative SLN patients. Method: SLN biopsy was performed in 499 
consecutive clinically N0 patients between 1997 and 2008. Following updated recommendations from the Melanoma 
Group of the European Organization of Research and Treatment of Cancer, degrees of SLN involvement were fully re- 
assessed for two anatomopathological parameters: tumour burden according to Rotterdam criteria (<0.1 mm, 0.1 - 1.0 
mm, and >1.0 mm) and microanatomic location according to Dewar (subcapsular, combined subcapsular and paren-
chymal, parenchymal, multifocal, or extensive). Minimally involved SLNs were defined as those with tumor burden 
<0.1 mm and/or subcapsular metastasis location. Kaplan-Meier and multivariable logistic regression analyses were per-
formed. Results: Out of 499 clinically N0 patients, positive SLNs were found in 123 patients (24.7 percent). With a 
median follow-up of 52 months (range: 9 - 146), five-year disease-free (DFS), disease-specific survival (DSS) and 
overall survival (OS) were 88.1, 93.9 and 89.9 percent for negative SLN patients, respectively. In minimally involved 
SLNs, there were 21 with tumour burden <0.1 mm, and 52 with subcapsular metastasis. Five-year DFS, DSS and OS in 
these sub-groups were 79.6, 86.6 and 86.6 percent, then 57.3, 69.8 and 67.8 percent respectively. DFS univariable 
analysis of these sub-groups compared to negative SLNs showed: (HR1.89, 95 percent CI 0.75 - 4.79; p 0.175) and (HR 
3.92, 95 percent CI 2.29 - 6.71; p < 0.0001) respectively. Minimally involved sub-groups were not predictive for NSLN 
negativity. Conclusion: Rotterdam’s tumour burden stratification is an easy and useful prognostic factor of melanoma 
survival. There was a trend showing that patients with SLN tumour burden <0.1 mm have a lower survival compared to 
SLN negative patients. One might suggest that patients with minimally involved SLNs may not be managed similarly to 
negative SLN patients. Subcapsular metastasis subgroup according to the microanatomic location has statistically sig-
nificant worst survival. 
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1. Introduction 
Since the first report in 1992 for melanoma patients [1], 
sentinel lymph node (SLN) biopsy has become a routine 
procedure in specialized centers for the management of 
intermediate risk, clinically localized cutaneous mela- 
noma. Lymphatic mapping with sentinel lymphadenec- 
tomy is a safe and effective surgical technique with lim-
ited morbidity [2]. The importance of the SLN status is 
now widely accepted as the most important prognostic 
factor [2,3]. In literature, positive SLN is found in 15 
percent to 30 percent of patients [3-8]. In case of positive  
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SLN, most centers recommend a completion lymph node 
dissection (CLND). However, additional positive non- 
sentinel lymph nodes (NSLN) are found in only about 20 
percent of CLND [3,5,7-10]. This means that radical 
lymph node dissection, with its consecutive morbidity 
[11], might be unnecessary in about three quarters of 
patients with positive SLN. Seeking for the optimal prac-
tice, the SLN status was sharpened in order to better pre-
dict NSLN status, recurrence rate and survival. Different 
classifications of positive SLN were proposed but none 
of these have gathered a wide acceptance [5,7-17]. Re-
cently, the EORTC Melanoma Group recommended a 
protocol to report the three following items per positive 
SLN [18]: (1) The microanatomic location of the metas-
tases according to Dewar for the entire node (A = sub-
capsular, B = combined subcapsular and parenchymal, C 
= parenchymal, D = multifocal, and E = extensive); (2) 
the SLN tumour burden according to the Rotterdam Cri-
teria for the maximum diameter of the largest metastasis 
expressed as an absolute number; and (3) the SLN tu-
mour burden stratified per category: <0.1 mm, 0.1 - 1.0 
mm, or >1.0 mm. 
The aim of this retrospective study of a prospective 
cohort was to analyze the results of the positive SLNs in 
a tertiary reference center for melanoma, to investigate 
prognostic factors for disease-free survival (DFS), dis- 
ease-specific survival (DSS) and overall survival (OS) in 
light of the EORTC recommendations protocol and pri- 
mary tumour criteria, and to compare minimally involved 
subgroups, such as tumour burden <0.1 mm, subcapsular 
metastasis, and SLN negative patients. Predictability of 
positive NSLNs was also analyzed.  
2. Patients and Methods 
2.1. Patients 
Between October 1997 and December 2008 all consecu-
tive SLN biopsy (SLNB) for melanoma patients were 
included prospectively in a database. SLNB was per-
formed by a single surgical team at the Centre Hospi-
talier Universitaire Vaudois (CHUV) in Switzerland. 
Inclusion criteria were primary skin melanoma >1.00 
mm without palpable adenopathy and absence of distant 
metastases (confirmed by CT scan or PET scan). Patients 
with melanoma thickness <1.00 mm in the presence of 
specific histopathologic factors, such as ulceration, re-
gression, or Clark level IV/V were also included. A 
CLND was usually proposed to patients with metastatic 
SLN. Patients with clinically metastatic lymph nodes 
were offered a therapeutic lymph node dissection and 
excluded from the present analysis. Patients with local 
recurrence of an earlier melanoma who also had a SLNB 
were excluded. The protocol of this study was accepted 
by the Institutional Ethical Committee.  
2.2. Surgical Technique and Pathological  
Analysis 
All patients underwent SLNB according to the triple 
technique as previously described (3). The SLN was de- 
fined as any blue node, the node with the highest radio- 
active count, and any node with >10 percent count rate of 
the most radioactive node. Any enlarged (>1 cm) suspi- 
cious node and some adjacent nodes (mainly for ana- 
tomical reason) were also dissected. SLNB was followed 
by initial melanoma scar wide excision (WE) with safety 
margins of 1 cm and 2 cm according to Breslow thick- 
ness of < = 1 mm and >1 mm respectively. SLN(s) were 
sent fresh or in formaldehyde solution directly to the 
University Institute of Pathology. Lymph nodes were 
bivalved and paraffin embedded. Three slices were cut 
for hematoxylin and eosin (H & E) and immunohisto- 
chemistry (IH) staining (Melan A and protein S100) at a 
regular 50 m interval at least six times following a 
SLNB protocol (3). No PCR analysis was performed. 
The CLND’s nodes were only processed with H-E stain- 
ing. An expert team from the Department of Pathology 
(E.S. & H.B.) reviewed all positive SLNs for the purpose 
of this study, according to the EORTC Melanoma Group 
recommended protocol [18]. Degrees of SLN involve- 
ment were fully re-assessed for two anatomopathological 
parameters: tumour burden according to Rotterdam crite- 
ria (<0.1 mm, 0.1 - 1.0 mm, and >1.0 mm) and microan- 
atomic location according to Dewar (subcapsular, com- 
bined subcapsular and parenchymal, parenchymal, mul- 
tifocal, or extensive). Minimally involved SLNs were 
defined as those with tumor burden <0.1 mm and/or sub- 
capsular metastasis location. 
2.3. Follow-Up 
A clinical follow-up was performed every 3 months dur- 
ing the first year after diagnosis, every 4 months during 
the second year, every 6 months during the 3rd, 4th and 5th 
years and then once a year. For patients with a Breslow 
more than 4 mm and for patients with positive SLN, a 
thoraco-abdominal scan was done once a year during the 
first five years following diagnosis. Most patients were 
followed at the outpatient clinic of the Oncology Unit in 
the same institution. Some patients were followed by 
their own dermatologists; their written follow-up was 
obtained after consent. Duration of follow-up was de- 
fined as time between date of SLN procedure and date of 
the last follow-up or death. 
2.4. Statistical Analysis 
Quantitative variables were compared using the Student 
or the Mann-Whitney test. Categorical variables were 
compared using the χ2 test. Univariable analysis of po-
tential prognostic factors was performed (Table 1). A  
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Table 1. Clinical and anatomopathological characteristics of 123 positive sentinel lymph nodes (SLNs) patients and univari-
able analyses of disease-free (DFS), disease-specific (DSS) and overall survival (OS). 
DFS DSS OS 
Characteristics Level Patients N = 123 HR 95% CI P HR 95% CI P HR 95% CI P 
Gender Female Male 
50 
73 
1 
2.14
 
1.2 - 3.8 
 
0.008
1 
2.57
 
1.2 - 5.3
 
0.011 
1 
2.58 
 
1.3 - 5.1
 
0.007
Age (mean ) ≤65 years >65 years 
84 
39 
1 
1.68
 
1.0 - 2.83
 
0.052
1 
1.50
 
0.8 - 2.9
 
0.230 
1 
1.57 
 
0.9 - 2.9
 
0.153
Melanoma subtype 
Superficial spreading 
Nodular 
Acral lentiginous 
Others 
42 
50 
15 
16 
1 
1.05
1.63
0.76
 
0.6 - 1.9 
0.7 - 3.6 
0.3 - 1.9 
 
0.870
0.220
0.545
1 
1.22
1.82
0.95
 
0.6 - 2.5
0.6 - 5.2
0.3 - 3.0
 
0.601 
0.265 
0.935 
1 
1.24 
1.67 
1.10 
 
0.6 - 2.5
0.6 - 4.7
0.4 - 3.1
 
0.544
0.331
0.861
Breslow thickness 
<1 mm 
1.01 - 2.0 mm 
2.01 - 4.0 mm 
>4.0 mm 
4 
41 
49 
29 
1 
1 
1.82
1.82
 
 
1.3 - 2.5 
1.3 - 2.5 
 
 
<0.0001
<0.0001
1 
1 
3.68
3.68
 
 
1.1 - 2.3
1.1 - 2.3
 
 
0.002 
0.002 
1 
1 
1.64 
1.64 
 
 
1.1 - 2.4
1.1 - 2.4
 
 
0.008
0.008
Clark level 
III 
IV 
V 
23 
89 
11 
1 
1.23
1.37
 
0.6 - 2.5 
0.5 - 3.8 
 
0.552
0.551
1 
1.41
1.21
 
0.6 - 3.4
0.3 - 4.9
 
0.440 
0.787 
1 
1.56 
1.63 
 
0.7 - 3.7
0.5 - 5.9
 
0.316
0.448
Ulceration Absent Present 
49 
74 
1 
2.21
 
1.3 - 3.7 
 
0.003
1 
2.16
 
1.1 - 4.1
 
0.018 
1 
2.38 
 
1.3 - 4.3
 
0.005
Primary melanoma 
location 
Extremity 
Head and neck 
Trunk 
63 
5 
55 
1 
1.68
1.09
 
0.5 - 5.5 
0.7 - 1.8 
 
0.393
0.729
1 
2.93
1.50
 
0.9 - 10.1
0.8 - 2.9
 
0.089 
0.226 
1 
2.41 
1.32 
 
0.7 - 8.2
0.7 - 2.5
 
0.157
0.379
Lymph node basin 1 >1 
92 
31 
1 
1.08
 
0.6 - 1.9 
 
0.789
1 
1.26
 
0.6 - 2.6
 
0.530 
1 
1.41 
 
0.7 - 2.7
 
0.314
SLN Tumour Burden 
<0.1 mm 
0.1 - 1 mm 
>1.0 mm 
Not available 
21 
33 
65 
4 
1 
2.58
4.50
 
 
0.9 - 7.3 
1.8 - 11.5
 
 
0.076
0.002
 
1 
2.14
3.35
 
 
0.7 - 6.9
1.2 - 9.7
 
 
0.203 
0.026 
 
1 
2.11 
3.69 
 
 
0.7 - 6.8
1.3 - 10.6
 
 
0.211
0.015
 
SLN Microanatomic  
tumour location* 
A 
B 
C 
D 
E 
Not available 
52 
18 
11 
8 
29 
5 
1 
1.45
0.74
1.32
3.31
 
 
0.7 - 3.2 
0.2 - 2.5 
0.5 - 3.9 
1.7 - 6.1 
 
 
0.363
0.635
0.611
<0.0001
 
1 
1.57
0.94
0.39
1.98
 
 
0.6 - 3.9
0.3 - 3.3
0.05 - 3.0
0.9 - 4.3
 
 
0.327 
0.927 
0.367 
0.081 
 
1 
1.69 
0.88 
0.37 
1.97 
 
 
0.7 - 4.0
0.3 - 3.0
0.05 - 2.8
1.0 - 4.1
 
 
0.232
0.841
0.334
0.070
 
*SLN Microanatomic tumour location according to Dewar (8): A, subcapsular. B, combined subcapsular and parenchymal. C, parenchymal. D, multifocal or E, 
extensive. HR, hazard ratio. CI, confidence interval. P, significance level. 
 
multivariable logistic regression model was used for the 
significant factors in the univariable analyses. Survival 
analyses involved the Kaplan-Meier method combined 
with log-rang test and multivariable Cox’s proportional 
hazard regression models. Statistical analyses were per-
formed with Stata 11 software (Stata Corp®). P values 
less than 0.05 were considered statistically significant. 
3. Results 
3.1. Patient Characteristics 
During the study period, 499 consecutive patients with 
primary skin melanoma and clinically N0 underwent a 
SLNB and were included in this study. Metastases to 
SLN(s) were detected in 123 (24.7 percent) patients. The 
median (range) Breslow thickness was 1.7 mm (0.3 - 15), 
1.5 mm (0.3 - 15), and 2.5 mm (0.8 - 12) for all patients, 
SLN negative and SLN positive patients respectively.  
For the same groups of patients, male ratios were 274/ 
499 (55 percent), 201/376 (54 percent) and 73/123 (59 
percent) respectively; ulceration rates were 126/499 (25 
percent), 77/376 (21 percent), 49/123 (40 percent) re-
spectively. Clinical and anatomopathologic characteris-
tics of the 123 SLN positive patients are presented in 
Table 1. All positive SLN were classified according to 
the recommendations from the EORTC Melanoma 
Group protocol published in 2009 (15). In four cases the 
pathological slides were not available for reassessment of 
the tumour burden and in five cases for the micro-
anatomic location. The four SLN positive patients who 
had melanoma with Breslow thickness 1.0 mm had a 
Breslow thickness close to 1.0 mm (n = 2) or Clark level 
IV (n = 2).  
3.2. Prognostic Factors 
The univariable Cox’s analysis of the 123 SLN positive 
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patients for DFS, DSS, and OS are presented in Table 1. 
Breslow thickness >2.0 mm, male gender, ulceration, 
SLN tumour burden >= 0.1 mm, and extensive micro- 
anatomic metastatic location (E) were significantly asso- 
ciated with worse DFS, DSS, and OS (p < 0.05). An age 
> 65 years was also significantly associated with worse 
DFS. On the multivariable analysis, Breslow thickness 
>2.0 mm (HR 3.01, 95 percent CI 1.51 - 6.04; p 0.002/ 
HR 3.27, 95 percent CI 1.40 - 7.66; p 0.006/HR 3.46, 95 
percent CI 1.49 - 8.05; p 0.004), ulceration (HR 1.74, 95 
percent CI 0.99 - 3.06; p 0.054/HR 2.13, CI 1.07 - 4.27; p 
0.032/HR 2.50, 95 percent CI 1.28 - 4.89; p 0.007), and 
SLN tumour burden >= 0.1 mm (HR 3.55, 95 percent CI 
1.30 - 9.66; p 0.013/HR 3.04, 95 percent CI 1.03 - 8.94; p 
0.044/HR 3.29, 95 percent CI 1.12 - 9.66; p 0.030) were 
independent significant factors lowering DFS, DSS, and 
OS. Male gender (HR 1.81, 95 percent CI 0.98 - 3.32; p 
0.057/HR 2.95, 95 percent CI 1.39 - 6.27; p 0.005/HR 
3.32, 95 percent CI 1.58 - 7.0; p 0.002) was an inde- 
pendent significant factor lowering DSS and OS. Exten- 
sive microanatomic metastatic location (E) was an inde- 
pendent significant factor lowering only DFS (HR 1.87, 
95 percent CI 1.05 - 3.35; p 0,033). The median SLN 
tumour burden in the extensive microanatomic location 
(E) was 7 mm (range: 0.8 - 15) compared to 0.15 mm 
(range 0.09 - 4) in the subcapsular microanatomic loca- 
tion (A) (HR 3.31, 95 percent CI 1.7 - 6.1; p < 0.001). 
3.3. Survival Analyses 
The median follow-up time for all 499 patients was 52 
months (range: 9 - 146). The median follow-up time for 
the 123 SLN positive patients was 41 months (range: 2 - 
146). The 3- and 5 - year DFS for SLN positive patients  
were 57.8 percent and 47.6 percent, compared to 92.3 
percent and 88.1 percent respectively for patients with a 
negative SLN. The 3- and 5-years DSS were 77.2 percent 
and 61.8 percent compared to 97.2 percent and 93.9 per-
cent; and OS were 75.4 percent and 59.1 percent com-
pared to 95.4 percent and 89.9 percent for the same pa-
tients respectively.  
3.4. Sentinel Lymph Node Positive Subgroups 
Analyses 
SLN positive subgroups DFS, DSS, and OS compared to 
negative SLN are presented in Table 2. SLN tumour 
burden subgroups 0.1 - 1 mm and >1 mm were signifi- 
cantly associated with worse survival. However, it did 
not reach statistical significance for the <0.1 mm sub- 
group. SLN microanatomic tumour location subgroups 
were all constantly significantly associated with a poorer 
survival, except for subgroups C and D. The 3- and 
5-years DFS, DSS, and OS for SLN positive subgroups 
compared to SLN negative patients are presented in Ta- 
ble 3. Tumour burden subgroups disease-free survival 
curves are shown in Figure 1. Global recurrence rate was 
5 (24 percent), 14 (42 percent), and 43 (66 percent) for 
Rotterdam subgroups <0.1 mm, 0.1 - 1 mm, and >1 mm 
respectively. Minimally involved SLN subcapsular sub- 
group A presented 20 recurrences (39 percent). There 
were 45 recurrences (12 percent) in the negative SLN. 
3.5. Predictive Factors for Non-Sentinel Lymph 
Node Metastasis 
Among the 123 patients with a positive SLN, 111 un- 
derwent a CLND. The procedure was not proposed to  
 
Table 2. Univariable analyses of sentinel lymph node (SLN)-positive subgroups of disease-free (DFS), disease-specific (DSS) 
and overall survival (OS) compared to SLN negative patients. 
DFS DSS OS 
SLN status Level N
HR 95% CI P HR 95% CI P HR 95% CI P 
SLN negative 376 1   1   1   
<0.1 mm 21 1.89 0.75 - 4.79 0.175 2.42 0.84 - 6.95 0.100 1.43 0.51 - 3.99 0.493 
0.1 - 1.0 mm 33 4.55 2.45 - 8.47 <0.0001 5.41 2.60 - 11.26 <0.0001 3.29 1.65 - 6.56 0.001 SLN Tumour Burden 
>1.0 mm 65 8.97 5.83 - 13.80 <0.0001 8.88 5.08 - 15.56 <0.0001 6.04 3.72 - 9.79 <0.0001
A 52 3.92 2.29 - 6.71 <0.0001 3.20 2.64 - 9.44 <0.0001 4.10 1.81 - 5.68 <0.0001
B 18 6.07 2.96 - 12.48 <0.0001 5.55 3.57 - 19.27 <0.0001 8.30 2.60 - 11.86 <0.0001
C 11 2.71 0.84 - 8.75 0.095 2.97 1.44 - 15.83 0.069 4.78 0.92 - 9.59 0.010 
D 8 5.08 1.82 - 14.17 0.002 1.08 0.25 - 13.68 0.942 1.85 0.15 - 7.82 0.545 
SLN  
Microanatomic 
tumour location* 
E 29 13.93 8.38 - 23.17 <0.0001 7.02 5.31 - 21.18 <0.0001 10.60 3.75 - 13.14 <0.0001
*SLN Microanatomic tumour location according to Dewar (8): A, subcapsular. B, combined subcapsular and parenchymal. C, parenchymal. D, multifocal or E, 
extensive. HR, hazard ratio. CI, confidence interval. P, significance level. 
Open Access                                                                                             JCT 
The Prognostic Value of Minimally Involved Melanoma Sentinel Lymph Nodes 1494 
 
Figure 1. Kaplan-Meier curves with log-rank test of tumour burden subgroups disease-free survival compared to negative 
sentinel nodes patients. 
 
Table 3. Sentinel lymph node (SLN) subgroups primary characteristics: Breslow thickness (median and range) and ulcera-
tion, the 3 and 5 years rates of disease-free (DFS), disease-specific (DSS) and overall survival (OS). 
3 years 5 years 
SLN status Level Breslow U 
DFS DSS OS DFS DSS OS 
SLN negative 1.5 (0.3 - 15) 20% 92.3 97.2 95.4 88.1 93.9 89.9 
<0.1 mm 2.3 (1.1 - 9) 38% 86.3 93.4 93.7 79.6 86.6 86.6 
0.1 - 1 mm 2.0 (1.0 - 6) 30% 64.4 83.1 83.4 52.7 68.7 68.5 SLN Tumour Burden 
>1 mm 3.0 (0.8 - 12) 48% 43.3 69.2 65.3 32.1 50.2 44.9 
A 2.4 (1.0 - 9) 37% 68.4 83.4 82.6 57.3 69.8 67.8 
B 2.8 (1.1 - 8) 33% 56.9 72.6 67.4 45.0 54.8 47.9 
C 2.0 (1.2 - 6) 36% 78.4 84.2 84.5 69.2 71.0 70.8 
D 2.7 (1.5 - 5) 38% 65.9 94.0 94.3 54.5 87.9 88.0 
SLN Microanatomic 
Tumour location* 
E 3.1 (0.8 - 12) 52% 32.0 66.7 63.9 22.6 47.9 44.0 
*SLN Microanatomic Tumour location according to Dewar (8): A, subcapsular, B, combined subcapsular and parenchymal, C, parenchymal, D, multifocal, or E, 
extensive. U, ulceration. 
 
three patients due to their poor general condition, and six 
further patients refused the procedure. A CLND was also 
not proposed to three patients between 1997 and 2000 
due to the very limited SLN invasion. Their SLNs were 
negative with H-E and had few metastatic cells detected 
in IH. One or more (median = 1, range = 1 - 4) positive 
non-sentinel nodes (NSLN) were found in 20 patients (18 
percent). The univariable analysis of these patients is 
presented in Table 4. On the multivariable analyses, ul- 
ceration (OR 6.51, 95 percent CI 1.91 - 22.13; p = 0.003)  
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Table 4. Predictive factors of positive non-sentinel lymph nodes (NSLNs). 
Positive NSLN = 20 Negative NSLN = 91  
Characteristics Level 
N % N % OR P 
Gender Female Male 
8 
12 
18 
18 
37 
54 
82 
82 
1 
1.03 
 
0.957 
Age (mean ) ≤ 65 years > 65 years 
11 
9 
14 
26 
65 
26 
86 
74 
1 
2.04 
 
0.157 
Melanoma subtype 
Superficial spreading 
Nodular 
Acrallentiginous 
Others 
5 
11 
2 
2 
12 
25 
18 
13 
36 
33 
9 
13 
88 
75 
82 
87 
1 
2.40 
1.60 
1.11 
 
0.138 
0.608 
0.909 
Breslow thickness 
<1 mm 
1.01 - 2.0 mm 
2.01 - 4.0 mm 
>4.0 mm 
0 
4 
11 
5 
- 
10 
28 
19 
4 
37 
29 
21 
100 
90 
73 
81 
1 
1 
1.57 
1.57 
 
 
0.135 
0.135 
Clark level III IV and V 
3 
17 
14 
19 
19 
72 
86 
81 
1 
1.50 
 
0.552 
Ulceration Absent Present 
6 
14 
9 
31 
60 
31 
91 
69 
1 
4.52 
 
0.005 
Primary melanoma loca-
tion 
Extremity 
Head and neck 
Trunk 
10 
3 
7 
18 
60 
14 
45 
2 
44 
82 
40 
86 
1 
6.75 
0.72 
 
0.051 
0.533 
SLN Tumour Burden 
<0.1 mm 
0.1 - 1 mm 
>1.0 mm 
Not available 
1 
5 
12 
2 
6 
17 
20 
 
16 
25 
49 
1 
94 
83 
80 
 
1 
3.20 
3.92 
 
 
0.308 
0.206 
 
SLN Microanatomic  
Tumour location* 
A 
B 
C 
D 
E 
Not available 
6 
2 
2 
0 
8 
2 
13 
13 
22 
0 
28 
 
40 
14 
7 
7 
21 
2 
87 
87 
78 
100 
72 
 
1 
0.95 
1.90 
- 
2.54 
 
 
0.955 
0.481 
- 
0.123 
 
*SLN Microanatomic tumour location according to Dewar (8): A, subcapsular. B, combined subcapsular and parenchymal. C, parenchymal. D, multifocal or E, 
extensive. OR, odd ratio. P, significance level. 
 
and primary local tumour in the head and neck (OR 
17.83, 95 percent CI 2.02 - 157.90; p = 0.010) were sig-
nificant predictive factors for NSLN positivity. The de-
gree of SLN involvement, with both studied classifica-
tions, was not a predictive factor of NSLN positivity. 
Among the 12 patients who did not undergo a CLND, 
four were in the minimally involved <0.1 mm subgroup 
and two of them recurred at 2 months and 4 years then 
deceased at 2 and 5 years respectively, another six pa-
tients were in the minimally involved subcapsular mi-
croanatomic location (A) and four of them recurred at 2, 
5, 6, and 24 months while three of them deceased at 1, 2, 
and 3 years.  
4. Discussion 
This single-institution-based study with surgical and an 
atomopathological dedicated teams confirmed that tu-
mour burden stratification according to Rotterdam crite-
ria is a useful prognostic factor for survival. Patients with 
SLN tumour burden <0.1 mm have a trend toward lower 
survival and toward higher recurrence rate, compared to 
SLN negative patients.  
The clinical and anatomopathologic characteristics of 
SLN positive patients in this study are comparable to 
those described in literature [7-10,13,15] in terms of age, 
primary melanoma location, male/female ratio, Clark 
level, and ulceration rate. However, the median Breslow 
thickness was 1.7 mm for all patients, and 2.45 mm for 
SLN positive patients. These Breslow data are among the 
lowest mentioned in literature [7,13,15], indicating that 
primary tumours were probably detected at an earlier 
stage. Despite this, 24.7 percent of metastatic SLN were 
detected in clinically negative patients, which is among 
the highest published rate [7-10,13,15]. The positive 
NSLN rate is comparable to those previously reported. 
The microanatomic location classification according to 
Dewar was intended to predict NSLN metastatic in-
volvement in the CLND following a SLNB procedure [5]. 
The subgroup with subcapsular metastasis (A) is consid-
ered to be in the early stage of metastatic invasion, with 
the hypothesis that metastatic cells have not yet contin-
ued to NSLN. However, in this study, 13 percent of the 
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patients with subcapsular metastasis presented a positive 
NSLN. Compared to negative SLN patients, the sub-
groups A, B, and E were associated with a higher recur-
rence rate and a poorer survival. The subgroups C and D 
comprised of such a small number of patients that they 
were therefore probably not associated with a poorer 
survival than negative SLN patients. 
Only subgroup E, with extensive metastasis, was an 
independent significant factor on multivariable analysis 
and negatively affected DFS. This was in fact partially 
related to the diameter, with a median SLN tumour bur- 
den significantly higher in the subgroup E compared to 
subgroup A. Additionally, the distribution of the different 
subgroups in this present study differed from its original 
description: we found 42 percent of patients with sub- 
capsular metastasis (i.e. subgroup A), as compared to 26 
percent in Dewar’s publication. This can be explained by 
the fact that this cohort of patients seems to have been 
diagnosed at an earlier stage. One may also hypothesize 
that the Dewar classification is difficult to reproduce, 
despite the fact that expert pathologists (ES, HB) pre-
cisely reviewed all slides. This suggests that microana- 
tomic location is not a useful tool for predicting survival 
or the NSLN status. 
Van Akkooi’s Rotterdam Criteria was specifically de- 
signed for survival analysis [7]. He convincingly demon- 
strated that the tumour burden threshold for SLN sub- 
micrometastases in melanoma should be <0.1 mm. With 
a slightly higher cut-off of <0.2 mm, the future of these 
patients is differed significantly [15]. Tumour burden 
within SLN is indeed an easy way to classify the degree 
of the SLN metastatic invasion in contrast to many other 
complicated classifications [16,19-21]. In his first publi- 
cations, Van Akkooi concluded that sub-micrometastases 
<0.1 mm could be considered as biologically false posi- 
tive, identical to SLN negative patients. Therefore, these 
patients could be spared a CLND and could be included 
into adjuvant therapy trials as SLN negative patients 
[7,22]. Van der Ploeg et al. [8-10] confirmed these con- 
clusions in the same institution, and mentioned seven 
patients from 2004 to 2008 who did not undergo CLND 
because of the presence of minimal SLN tumour burden 
(<0.1 mm). By interest, the issue of minimally involved 
SLN was initially also debated in this institution. Three 
among the earlier patients treated in this cohort were not 
proposed a CLND. In the present study, only tumour 
burden > = 0.1 mm was a significant independent factor 
worsening DFS, DSS and OS. Sub-micrometastases 
(<0.1 mm) was not a significant independent factor for 
survival. However, there was a trend towards worse out- 
comes for patients with sub-micrometastases in com- 
parison to SLN negative patients. It could be hypothe- 
sized that this trend did not reach statistical significance 
due to the small number of patients (21 in the sub-mi- 
crometastatic subgroup), therefore not permitting a gen-
eralization on a larger scale. Global recurrence rates also 
rose following an increase of the metastatic charge ex-
pressed as tumour burden. However, even in the sub- 
micrometastatic group, five patients recurred: four pa- 
tients presented initially local recurrence, and one patient 
had directly distant metastases. Only one patient in sub- 
micrometastatic subgroup had a positive NSLN. The 
Rotterdam criteria satisfactory allow a stratification of 
the prognosis of patients with positive SLN. Although 
CLND did not influence survival in cohort studies [23], 
there is no data from randomized controlled trials. That is 
why; the issue remains debated waiting for the ongoing 
prospective study MLST II results. The European con- 
sensus multidisciplinary based guideline 2012 did not cut 
the issue of CLND for sub-micrometastatic subgroup 
[24]. 
Some authors attempted to integrate various elements 
in scores, taking into account the primary melanoma 
characteristics and the metastatic charge of the SLN, but 
until now these scores failed to reach two goals. The first 
one is to find out the least invasive but the most secure 
care program for a subgroup of positive SLN who are 
unlikely to recur and have similar survival compared to 
negative SLN. The second goal is to identify patients 
with micrometastatic SLNs who have no positive NSLN 
and thus can be considered as negative SLN. Taking into 
account the present clinical data, one would challenge at 
this point that such a classification might be possible. As 
shown in this study, even a very limited SLN invasion 
had a trend toward lower survival and could be associ- 
ated with positive NSLN. If other primary tumour char- 
acteristic restrictions are added to the sub-microscopic 
subgroup, a real subgroup acting as negative SLN might 
be found. In this case, it would restrict this subgroup so 
much that it would apply to a very limited number of 
patients and thus lose its clinical significance.   
5. Conclusion 
Tumour burden stratification according to Rotterdam 
criteria is an easy and useful prognostic factor of survival 
in melanoma. There was a trend showing that patients 
with SLN sub-micrometastases <0.1 mm had a lower sur- 
vival compared to SLN negative patients. One might 
suggest that patients with minimally involved SLNs may 
not be managed similarly to negative SLN patients. Our 
results suggest that micro-anatomic location according to 
Dewar is not a useful tool for predicting survival and the 
NSLN status 
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